The melanoma update is deliberately narrow: how prospective CP-GEP data may inform the sentinel-node conversation, what 10-year CheckMate 067 follow-up says about the durability of modern immunotherapy, and how RP1 plus nivolumab expands the post–PD-1 treatment landscape.
Three themes
01
Predict better
MERLIN_001 provides prospective, blinded evidence on CP-GEP as a tool to refine sentinel-node risk assessment.
02
Appreciate the durability
CheckMate 067 at 10 years shows how long-term survival has become a defining feature of metastatic melanoma treatment.
03
Add an option after PD-1
RP1 plus nivolumab introduces a newly approved oncolytic-immunotherapy option for selected PD-1–refractory advanced melanoma.
View the presentationOpen the web-based Reveal.js slide deck.
Launch slides →
Presented as part of Skin Cancer Forum Part II at the 27th Annual Las Vegas Dermatology Seminar, Bellagio, Las Vegas. Conference agenda.
This site represents our opinions only. See our full
Disclaimer and
Terms of Use Agreement.